Canaccord analyst Richard Close raised the firm’s price target on Quipt Home Medical (QIPT) to $2.30 from $1.70 and keeps a Hold rating on the shares. The firm said they demonstrated improvement in 3Q with a sequential uptick across metrics, though it remains down year over year as the company works through some headwinds such as its Humana MA (HUM) capitated contract and disposable supply contract non-renewal.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QIPT:
- Quipt Home Medical Corp Faces Shareholder Activism Challenges: Implications for Operations and Market Stability
- Quipt Home Medical Expands Midwest Presence Through Strategic Joint Venture
- Quipt Home partners with three major health systems to form joint venture
- Quipt Home Medical Achieves Positive Growth and Expands Reach with Strategic Acquisition
- QIPT Upcoming Earnings Report: What to Expect?